Upcoming strategies for the treatment of metastatic melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-04

AUTHORS

Francesco Spagnolo, Paola Queirolo

ABSTRACT

Prognosis for advanced and metastatic melanoma is poor, with a 5-year survival of 78, 59 and 40% for patients with stage IIIA, IIIB and IIIC, respectively, and a 1-year survival of 62% for M1a, 53% for M1b and 33% for M1c. The unsatisfactory results of actual standard therapies for metastatic melanoma highlight the need for effective new therapeutic strategies. Several drugs, including BRAF, KIT and MEK inhibitors, are currently being evaluated after promising data from Phase I and Phase II studies; Vemurafenib, a BRAF-inhibitor agent, has been approved by the Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation after a significant impact on both progression-free and overall survival was demonstrated compared with dacarbazine in a Phase III trial. Ipilimumab, an immunotherapeutic drug, has proven to be capable of inducing long-lasting responses and was approved for patients with advanced melanoma in first- and second-line treatment by the FDA and in second-line treatment by the European Medicines Agency. Furthermore, a significant survival benefit of the combination of ipilimumab with dacarbazine compared with dacarbazine alone for first-line treatment was reported. In the near future, patients with BRAF mutations could have the chance to benefit from treatment with BRAF inhibitors; patients harboring BRAF or NRAS mutations could be treated with MEK inhibitors; finally, the subgroup of patients with acral, mucosal or chronic sun-damaged melanoma harboring a KIT mutation could benefit from KIT inhibitors. Ipilimumab could become a standard treatment for metastatic melanoma, both as a single agent and in combination; its efficacy has been proven, and researchers should now address their efforts to understanding the predictive variables of response to treatment. More... »

PAGES

177-184

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00403-012-1223-7

DOI

http://dx.doi.org/10.1007/s00403-012-1223-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027554928

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22350184


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dacarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipilimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MAP Kinase Kinase Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins B-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-kit", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Plastic and Reconstructive Surgery, IRCCS Azienda Ospedaliera Universitaria San Martino \u2013 IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi, 10, 16132, Genoa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spagnolo", 
        "givenName": "Francesco", 
        "id": "sg:person.01261247072.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261247072.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino \u2013 IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi, 10, 16132, Genoa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Queirolo", 
        "givenName": "Paola", 
        "id": "sg:person.01102114523.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102114523.12"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.2147/cmr.s6073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005739869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005810239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2010.11.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006637390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-2200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010952678"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1002011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012824919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.4799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013277178"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.0707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013453815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.leukres.2011.01.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016672620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(94)90456-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017447576"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-06-0084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018662778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.20866", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019747312"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602529", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024663272", 
          "https://doi.org/10.1038/sj.bjc.6602529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602529", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024663272", 
          "https://doi.org/10.1038/sj.bjc.6602529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1593/neo.101466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025380746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025653897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2011.746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028680620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.7636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034168619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21834", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034695273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21834", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034695273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1104621", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036355137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djq310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037022855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.9275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038427267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039293072", 
          "https://doi.org/10.1038/sj.bjc.6604482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-2346", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039294598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041864150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m600197200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044159237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1755-148x.2008.00475.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048947620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00194546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051909215", 
          "https://doi.org/10.1007/bf00194546"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2010.09.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051966156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jid.2008.44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053118447", 
          "https://doi.org/10.1038/jid.2008.44"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.sder.2010.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054747867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.sder.2010.10.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054747876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.08.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.08.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/187152011795347469", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069218395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/187152011795347469", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069218395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.7.2105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.1.158", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074572226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078343060", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082470506", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1995.13.12.2895", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082843343"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-04", 
    "datePublishedReg": "2012-04-01", 
    "description": "Prognosis for advanced and metastatic melanoma is poor, with a 5-year survival of 78, 59 and 40% for patients with stage IIIA, IIIB and IIIC, respectively, and a 1-year survival of 62% for M1a, 53% for M1b and 33% for M1c. The unsatisfactory results of actual standard therapies for metastatic melanoma highlight the need for effective new therapeutic strategies. Several drugs, including BRAF, KIT and MEK inhibitors, are currently being evaluated after promising data from Phase I and Phase II studies; Vemurafenib, a BRAF-inhibitor agent, has been approved by the Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation after a significant impact on both progression-free and overall survival was demonstrated compared with dacarbazine in a Phase III trial. Ipilimumab, an immunotherapeutic drug, has proven to be capable of inducing long-lasting responses and was approved for patients with advanced melanoma in first- and second-line treatment by the FDA and in second-line treatment by the European Medicines Agency. Furthermore, a significant survival benefit of the combination of ipilimumab with dacarbazine compared with dacarbazine alone for first-line treatment was reported. In the near future, patients with BRAF mutations could have the chance to benefit from treatment with BRAF inhibitors; patients harboring BRAF or NRAS mutations could be treated with MEK inhibitors; finally, the subgroup of patients with acral, mucosal or chronic sun-damaged melanoma harboring a KIT mutation could benefit from KIT inhibitors. Ipilimumab could become a standard treatment for metastatic melanoma, both as a single agent and in combination; its efficacy has been proven, and researchers should now address their efforts to understanding the predictive variables of response to treatment.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00403-012-1223-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054393", 
        "issn": [
          "0340-3696", 
          "1432-069X"
        ], 
        "name": "Archives of Dermatological Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "304"
      }
    ], 
    "name": "Upcoming strategies for the treatment of metastatic melanoma", 
    "pagination": "177-184", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "83439f867c3e24f014b76e265b95d61d5d9df70e7e26c8aaf9e67a12762422ff"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22350184"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8000462"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00403-012-1223-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027554928"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00403-012-1223-7", 
      "https://app.dimensions.ai/details/publication/pub.1027554928"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00403-012-1223-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00403-012-1223-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00403-012-1223-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00403-012-1223-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00403-012-1223-7'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      84 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00403-012-1223-7 schema:about N0c56af2fce044ade9e553beff650313c
2 N1780f9d83a724c12b59fd7cb5aae5ad0
3 N23c1ce402b2a4c1faec4af393142c0e7
4 N272afd86bec54ccca476bddfd581e390
5 N63f724bd84754094875d8490c44f7fa8
6 N692ee44dacd84618a1cf4c60b5ba1b39
7 N69c1963c8b7d4049b4b18f50526ec809
8 N8bc7ba82005a4c5ebabcaa74df4b3241
9 N938a4216015e44428d117ac94cbfe664
10 N95114f5a752d44a6accd3c62e6c89848
11 Na181caecb9a04508bad310f40cc049e4
12 Na343da53826945bcb5200d04a3d8c7f6
13 Na74331e85299469e8e12655f45190c61
14 Nb4de2a2962684dbb9bd21d42e482e635
15 Ncdc562bc19914c13ab6b7e255c079b13
16 Neb803d90ed684f7385251b8541bb9360
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N6f6083f7545b401791f78bfe5801fa31
20 schema:citation sg:pub.10.1007/bf00194546
21 sg:pub.10.1038/jid.2008.44
22 sg:pub.10.1038/nature00766
23 sg:pub.10.1038/sj.bjc.6602529
24 sg:pub.10.1038/sj.bjc.6604482
25 https://app.dimensions.ai/details/publication/pub.1078343060
26 https://app.dimensions.ai/details/publication/pub.1082470506
27 https://doi.org/10.1001/jama.2011.746
28 https://doi.org/10.1002/cncr.20866
29 https://doi.org/10.1002/cncr.21834
30 https://doi.org/10.1016/0959-8049(94)90456-1
31 https://doi.org/10.1016/j.ccr.2010.11.023
32 https://doi.org/10.1016/j.leukres.2011.01.021
33 https://doi.org/10.1016/j.sder.2010.06.005
34 https://doi.org/10.1016/j.sder.2010.10.005
35 https://doi.org/10.1053/j.seminoncol.2010.09.014
36 https://doi.org/10.1056/nejmoa1002011
37 https://doi.org/10.1056/nejmoa1003466
38 https://doi.org/10.1056/nejmoa1103782
39 https://doi.org/10.1056/nejmoa1104621
40 https://doi.org/10.1074/jbc.m600197200
41 https://doi.org/10.1093/annonc/mdq013
42 https://doi.org/10.1093/jnci/djq310
43 https://doi.org/10.1111/j.1755-148x.2008.00475.x
44 https://doi.org/10.1158/1078-0432.ccr-08-0575
45 https://doi.org/10.1158/1078-0432.ccr-10-2200
46 https://doi.org/10.1158/1078-0432.ccr-10-2346
47 https://doi.org/10.1158/1535-7163.mct-06-0084
48 https://doi.org/10.1200/jco.1995.13.12.2895
49 https://doi.org/10.1200/jco.1999.17.7.2105
50 https://doi.org/10.1200/jco.2000.18.1.158
51 https://doi.org/10.1200/jco.2005.08.036
52 https://doi.org/10.1200/jco.2007.14.0707
53 https://doi.org/10.1200/jco.2007.15.7636
54 https://doi.org/10.1200/jco.2009.23.4799
55 https://doi.org/10.1200/jco.2010.33.9275
56 https://doi.org/10.1593/neo.101466
57 https://doi.org/10.2147/cmr.s6073
58 https://doi.org/10.2174/187152011795347469
59 schema:datePublished 2012-04
60 schema:datePublishedReg 2012-04-01
61 schema:description Prognosis for advanced and metastatic melanoma is poor, with a 5-year survival of 78, 59 and 40% for patients with stage IIIA, IIIB and IIIC, respectively, and a 1-year survival of 62% for M1a, 53% for M1b and 33% for M1c. The unsatisfactory results of actual standard therapies for metastatic melanoma highlight the need for effective new therapeutic strategies. Several drugs, including BRAF, KIT and MEK inhibitors, are currently being evaluated after promising data from Phase I and Phase II studies; Vemurafenib, a BRAF-inhibitor agent, has been approved by the Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation after a significant impact on both progression-free and overall survival was demonstrated compared with dacarbazine in a Phase III trial. Ipilimumab, an immunotherapeutic drug, has proven to be capable of inducing long-lasting responses and was approved for patients with advanced melanoma in first- and second-line treatment by the FDA and in second-line treatment by the European Medicines Agency. Furthermore, a significant survival benefit of the combination of ipilimumab with dacarbazine compared with dacarbazine alone for first-line treatment was reported. In the near future, patients with BRAF mutations could have the chance to benefit from treatment with BRAF inhibitors; patients harboring BRAF or NRAS mutations could be treated with MEK inhibitors; finally, the subgroup of patients with acral, mucosal or chronic sun-damaged melanoma harboring a KIT mutation could benefit from KIT inhibitors. Ipilimumab could become a standard treatment for metastatic melanoma, both as a single agent and in combination; its efficacy has been proven, and researchers should now address their efforts to understanding the predictive variables of response to treatment.
62 schema:genre research_article
63 schema:inLanguage en
64 schema:isAccessibleForFree false
65 schema:isPartOf Nad6e97f1643c4f348081ae3e5e300843
66 Nee2cae3d7d084369a29fa3c47086637a
67 sg:journal.1054393
68 schema:name Upcoming strategies for the treatment of metastatic melanoma
69 schema:pagination 177-184
70 schema:productId N2cf2409a86114a8fbe4045b9c8c826df
71 N7fec03fd2e9f4bf9ad365486a3b47fd7
72 N9fcbef454bdd4194a9515a7444774c21
73 Ncf82a0912edd4d9da956116837d9f401
74 Ne65a213b024f4851ab09085eb71983ca
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027554928
76 https://doi.org/10.1007/s00403-012-1223-7
77 schema:sdDatePublished 2019-04-11T02:01
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher Nd4dba0754b9c436881205595cc610faf
80 schema:url http://link.springer.com/10.1007%2Fs00403-012-1223-7
81 sgo:license sg:explorer/license/
82 sgo:sdDataset articles
83 rdf:type schema:ScholarlyArticle
84 N0c56af2fce044ade9e553beff650313c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Antineoplastic Combined Chemotherapy Protocols
86 rdf:type schema:DefinedTerm
87 N1780f9d83a724c12b59fd7cb5aae5ad0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Proto-Oncogene Proteins c-kit
89 rdf:type schema:DefinedTerm
90 N23c1ce402b2a4c1faec4af393142c0e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Indoles
92 rdf:type schema:DefinedTerm
93 N272afd86bec54ccca476bddfd581e390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Antineoplastic Agents
95 rdf:type schema:DefinedTerm
96 N2cf2409a86114a8fbe4045b9c8c826df schema:name dimensions_id
97 schema:value pub.1027554928
98 rdf:type schema:PropertyValue
99 N63f724bd84754094875d8490c44f7fa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Skin Neoplasms
101 rdf:type schema:DefinedTerm
102 N692ee44dacd84618a1cf4c60b5ba1b39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Ipilimumab
104 rdf:type schema:DefinedTerm
105 N69c1963c8b7d4049b4b18f50526ec809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antibodies, Monoclonal
107 rdf:type schema:DefinedTerm
108 N6f6083f7545b401791f78bfe5801fa31 rdf:first sg:person.01261247072.50
109 rdf:rest N9a4e0e3126e841b1bb74d8a59579ae8f
110 N7fec03fd2e9f4bf9ad365486a3b47fd7 schema:name nlm_unique_id
111 schema:value 8000462
112 rdf:type schema:PropertyValue
113 N8bc7ba82005a4c5ebabcaa74df4b3241 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Dacarbazine
115 rdf:type schema:DefinedTerm
116 N938a4216015e44428d117ac94cbfe664 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N95114f5a752d44a6accd3c62e6c89848 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Protein Kinase Inhibitors
121 rdf:type schema:DefinedTerm
122 N9a4e0e3126e841b1bb74d8a59579ae8f rdf:first sg:person.01102114523.12
123 rdf:rest rdf:nil
124 N9fcbef454bdd4194a9515a7444774c21 schema:name doi
125 schema:value 10.1007/s00403-012-1223-7
126 rdf:type schema:PropertyValue
127 Na181caecb9a04508bad310f40cc049e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Neoplasm Metastasis
129 rdf:type schema:DefinedTerm
130 Na343da53826945bcb5200d04a3d8c7f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Sulfonamides
132 rdf:type schema:DefinedTerm
133 Na74331e85299469e8e12655f45190c61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name MAP Kinase Kinase Kinases
135 rdf:type schema:DefinedTerm
136 Nad6e97f1643c4f348081ae3e5e300843 schema:issueNumber 3
137 rdf:type schema:PublicationIssue
138 Nb4de2a2962684dbb9bd21d42e482e635 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Clinical Trials as Topic
140 rdf:type schema:DefinedTerm
141 Ncdc562bc19914c13ab6b7e255c079b13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Melanoma
143 rdf:type schema:DefinedTerm
144 Ncf82a0912edd4d9da956116837d9f401 schema:name readcube_id
145 schema:value 83439f867c3e24f014b76e265b95d61d5d9df70e7e26c8aaf9e67a12762422ff
146 rdf:type schema:PropertyValue
147 Nd4dba0754b9c436881205595cc610faf schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 Ne65a213b024f4851ab09085eb71983ca schema:name pubmed_id
150 schema:value 22350184
151 rdf:type schema:PropertyValue
152 Neb803d90ed684f7385251b8541bb9360 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Proto-Oncogene Proteins B-raf
154 rdf:type schema:DefinedTerm
155 Nee2cae3d7d084369a29fa3c47086637a schema:volumeNumber 304
156 rdf:type schema:PublicationVolume
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
161 schema:name Oncology and Carcinogenesis
162 rdf:type schema:DefinedTerm
163 sg:journal.1054393 schema:issn 0340-3696
164 1432-069X
165 schema:name Archives of Dermatological Research
166 rdf:type schema:Periodical
167 sg:person.01102114523.12 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
168 schema:familyName Queirolo
169 schema:givenName Paola
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102114523.12
171 rdf:type schema:Person
172 sg:person.01261247072.50 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
173 schema:familyName Spagnolo
174 schema:givenName Francesco
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261247072.50
176 rdf:type schema:Person
177 sg:pub.10.1007/bf00194546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051909215
178 https://doi.org/10.1007/bf00194546
179 rdf:type schema:CreativeWork
180 sg:pub.10.1038/jid.2008.44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053118447
181 https://doi.org/10.1038/jid.2008.44
182 rdf:type schema:CreativeWork
183 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
184 https://doi.org/10.1038/nature00766
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/sj.bjc.6602529 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024663272
187 https://doi.org/10.1038/sj.bjc.6602529
188 rdf:type schema:CreativeWork
189 sg:pub.10.1038/sj.bjc.6604482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039293072
190 https://doi.org/10.1038/sj.bjc.6604482
191 rdf:type schema:CreativeWork
192 https://app.dimensions.ai/details/publication/pub.1078343060 schema:CreativeWork
193 https://app.dimensions.ai/details/publication/pub.1082470506 schema:CreativeWork
194 https://doi.org/10.1001/jama.2011.746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028680620
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1002/cncr.20866 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019747312
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1002/cncr.21834 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034695273
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/0959-8049(94)90456-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017447576
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.ccr.2010.11.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006637390
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.leukres.2011.01.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016672620
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/j.sder.2010.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054747867
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/j.sder.2010.10.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054747876
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1053/j.seminoncol.2010.09.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051966156
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1056/nejmoa1002011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012824919
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1056/nejmoa1103782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041864150
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1056/nejmoa1104621 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036355137
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1074/jbc.m600197200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044159237
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1093/annonc/mdq013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025653897
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1093/jnci/djq310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037022855
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1111/j.1755-148x.2008.00475.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048947620
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1158/1078-0432.ccr-08-0575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005810239
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1158/1078-0432.ccr-10-2200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010952678
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1158/1078-0432.ccr-10-2346 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039294598
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1158/1535-7163.mct-06-0084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018662778
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.1995.13.12.2895 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082843343
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.1999.17.7.2105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549817
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2000.18.1.158 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074572226
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2005.08.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204285
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2007.14.0707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013453815
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2007.15.7636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034168619
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2009.23.4799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013277178
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2010.33.9275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038427267
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1593/neo.101466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025380746
253 rdf:type schema:CreativeWork
254 https://doi.org/10.2147/cmr.s6073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005739869
255 rdf:type schema:CreativeWork
256 https://doi.org/10.2174/187152011795347469 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069218395
257 rdf:type schema:CreativeWork
258 https://www.grid.ac/institutes/grid.410345.7 schema:alternateName Ospedale San Martino
259 schema:name Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi, 10, 16132, Genoa, Italy
260 Plastic and Reconstructive Surgery, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi, 10, 16132, Genoa, Italy
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...